Your SlideShare is downloading. ×
Lung Cancer:  Clinical Trial Overview
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Lung Cancer: Clinical Trial Overview

268
views

Published on

This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial …

This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics:
Phase of study
Study type distribution (expanded access, interventional, observational)
Length of trials
Patient enrollment
Study sponsors
Regional breakdown

Download the full preview: http://www.isrreports.com/product/lung-cancer-clinical-trial-overview/

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
268
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Lung Cancer: Clinical Trial Overview Info@ISRreports.com ©2014 Industry Standard Research www.ISRreports.com PREVIEW
  • 2. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 2 act with confidence Report Introduction: This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: • Phase of study • Study type distribution (expanded access, interventional, observational) • Length of trials • Patient enrollment • Study sponsors • Regional breakdown 41 Pages Q2, 2014 Publication Date 33 Charts and Graphs Major Sections: How you can use this report: 1. Introduction 2. Lung Cancer Clinical Trial Analysis 3. Average Clinical Trial Enrollment 4. Study Sponsor Analysis by Phase 5. Regional Analysis • Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials • Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages • Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally NEXT: Sponsors Included
  • 3. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 3 act with confidence • Actavis • Agennix • American College of Radiology • Amgen • AstraZeneca • Betta Pharmaceuticals • Biocad • Boehringer Ingelheim • Bristol-Myers Squibb • Celgene Corporation • Cell Therapeutics • Cell>Point • Chong Kun Dang Pharmaceutical • Eisai • Eli Lilly and Company • EMD Serono • Genentech • Gilead Sciences • GlaxoSmithKline • Helsinn Therapeutics (U.S.) • Hoffmann-La Roche • InSightec • J. Uriach and Company • Janssen Korea • Jiangsu HengRui Medicine Co. • Kael-GemVax Co. • MedImmune • Merck KGaA • Neomend • Novartis Pharmaceuticals • Peregrine Pharmaceuticals • Pfizer • Pierre Fabre Pharma GmbH • Sanofi • Swami Rama Cancer Hospital and Research Institute • Synta Pharmaceuticals • Teva Pharmaceutical Industries • Veran Medical Technologies • Yantai Medgenn Sponsors Included:
  • 4. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 4 act with confidence Table of Contents For full table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/lung-cancer-clinical-trial-overview/
  • 5. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 5 act with confidence act with confidence Introduction www.ISRreports.com ©2014 | Lung Cancer: Clinical Trial Overview 7 Overview Lung cancer is one of the most destructive, difficult to detect, and deadly forms of cancer� There are two distinct forms of lung cancer: small-cell and non-small cell lung cancer� Roughly 80% of all lung cancer cases are non-small cell lung cancer� Often, both small cell and non-small cell lung cancer will spread to other parts of the body� In addition to the risk of lung cancer spreading, it is also very difficult to detect in its earliest stages since there are often no symptoms until the cancer is highly advanced� Though lung cancer is often associated with cigarette smoking, there are multiple causes including radon exposure, industrial exposures, and genetic factors� The number of different causes for lung cancer leads to difficulty in diagnosis and treatment� Imaging tests such as CT, PET and bone scans are the primary means by which the threat of lung cancer is identified� Bronchoscopies, ultrasounds, mediastinoscopies, mediastinotomies, thoracentesis, thoracoscopies, sputum cytology, and fine needle biopsies are then often used to actually diagnose the cancer� Clinical trials play a consistent role in the treatment of lung cancer since there is no de facto standard procedure or therapy used to rid patients of the disease� New drugs, therapies and medical devices are constantly being introduced to the clinical stages of development� This report reviews the current clinical trial activity surrounding lung cancer� Specifically, ISR has examined those clinical trial studies that “Industry” has helped fund� www�clinicaltrials�gov allows the sorting of studies based on the “funder type” with the following options: NIH, Industry, Other U�S Federal Agency, and All Others (Individual, University, Organization, …)� This report focuses only on those studies that have listed “Industry” as the funder type� A number of data points relating to lung cancer clinical trials are outlined in detail in the following sections of this report: • Phase of study • Study type distribution (expanded access, interventional, observational) • Length of trails • Patient enrollment • Regional breakdown Sample Page
  • 6. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 6 act with confidence act with confidence Introduction www.ISRreports.com ©2014 | Lung Cancer: Clinical Trial Overview 6 Lung cancer claims more lives each year than do colon, prostate, ovarian and breast cancers combined. 39,620 Breast Cancer 50,310 Colon Cancer 14,270 Ovarian Cancer 159,260Lung Cancer ONE IN 14 PEOPLEWILL DEVELOP LUNG CANCER. DEATHS PER YEAR TREATMENT 2/3 OF PEOPLE WITH LUNG CANCER ARE DIAGNOSED AT AGE 65 OR OLDER AT LEAST 80% OF LUNG CANCER DEATHS ARE THOUGHT TO RESULT FROM SMOKING. For stage I and II, surgery remains the primary treatment . Patients often undergo either radiation therapy, systemic chemotherapy, molecular-targeted therapy, stage-based management or a combination of these. + + LUNG CANCERIS THE LEADING CAUSE OF CANCER DEATH. Sources: ISR Reports, cancer�org, cancer�gov, mayoclinic�org, dailyinfographic�org Sample Page
  • 7. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 7 act with confidence Sample Page For full table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/lung-cancer-clinical-trial-overview/
  • 8. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 8 act with confidence Ordering Information Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services indus- tries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. About Industry Standard Research Save on this, or any ISR report, by registering a free account Register now • Receive a $250 instant credit towards any ISR report • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources For pricing and ordering information, please visit our website: http://www.isrreports.com/product/lung-cancer-clinical-trial-overview/
  • 9. www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 9 act with confidence www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 9 act with confidence The ISR Difference Custom-quality syndicated market research www.ISRreports.com ISR's Reports The Common Syndicated Reportvs. How confident are you? vs. DataCollection ISR's proprietary data collection tools and channels support fast, high quality data collection Struggle to recruit the right targets and enough of them vs. SampleSizes Robust sample sizes that instill confidence Often insufficient industry representation that leaves you defending results vs. Research methods Mostly primary research; always appropriate for the topic One size fits all; usually publically available data vs.vs. Respondents Sophisticated screening ensures genuine decision-makers Undisclosed methodologies and respondent demographics vs.vs. Analysts Decades of experience means more insights that are immediately usable Junior analysts capable of reporting numbers